It has long been a controversial theory about Alzheimer’s disease, often dismissed by experts as a sketchy cul-de-sac off the beaten path from mainstream research. But a new study by a team that includes prominent Alzheimer’s scientists who were previously skeptics of this theory may well change that. The research offers ...
June 22, 2018
Photo credit: Ben Watts Nationally recognized Cure Alzheimer’s Fund researchers Dr. Rudy Tanzi and Dr. Sam Gandy add another distinction to their scientific careers as they join rock celebrities Sheryl Crow, Josh Groban, hip hop artist and X-Men Origins: Wolverine co-star Will-i-am, Aerosmith’s Joe Perry; and Seal for a designer menswear ...
May 20, 2009
January 30, 2024
January 30, 2024
January 30, 2024
The goal of this project is to develop genetically modified human neural progenitor cells that can replicate Alzheimer’s disease pathology in in vitro and in vivo conditions in order to develop and test Alzheimer disease drugs in human brain cells. This work represents a potential major breakthrough in the use of ...
November 9, 2011
A new Alzheimer’s disease (AD) model suggests that defects in the blood-brain barrier (BBB) play a key role in worsening amyloid plaques and neurofibrillary tangles, and that therapies to reduce gaps in the BBB hold promise for treatment of the disease. The new model uses “microfluidics” to examine how a layer ...
October 9, 2019
“I’m trying to keep this ship afloat. I’m trying not to lose hope,” are the opening lyrics to “Level Best,” a song co-written by Mila Maring-Sims, caregiver for her husband Kelley, who was diagnosed with early-onset Alzheimer’s disease in 2014. “As members of several bluegrass bands, my husband and I ...
March 14, 2017
Topline: A safety study published in The New England Journal of Medicine assessed the use of focused ultrasound (FUS) with anti-amyloid immunotherapy aducanumab (marketed as Aduhelm) in three patients with mild cognitive impairment and amyloid pathology. Each person was treated for six months with aducanumab delivered through FUS on just one ...
January 30, 2024
We built an iterative scheme of “modeling->screening->validation” through the collaboration within the AD4 consortium. More than 3,000 compounds were physically screened through automated imaging of the 3D Alzheimer’s in a Dish™ assay developed by AD4 consortium collaborators, and nearly 30 compounds have shown an ability to significantly reduce the level ...
February 17, 2022
